GlassScriptPhysician profile
Andrew Covey
NPI 1245785187
$1,147.96
in general payments reported to CMS, 2019-2025
23 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.84 · 2022: $253 · 2023: $258 · 2024: $346 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $212.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $145.01 | 2022-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $120.55 | 2023-2025 | Korlym |
| Abbott Laboratories | $77.78 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $52.15 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $49.10 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.48 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $44.03 | 2024 | |
| Dendreon Pharmaceuticals LLC | $41.90 | 2024 | Provenge |
| Eisai INC. | $41.68 | 2022-2024 | |
| Glaxosmithkline, LLC. | $40.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.90 | 2022 | |
| Exact Sciences Corporation | $30.75 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $29.10 | 2024 | |
| Corium, LLC | $27.10 | 2023 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $25.37 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.21 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $20.83 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.35 | 2023 | Oxlumo |
| Amgen INC. | $17.25 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $16.59 | 2023 | Dexcom G6 Transmitter |
| Karyopharm Therapeutics INC. | $16.11 | 2024 | Xpovio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.14 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Covey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.